Cargando…

A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains

Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidwell, L. Cinnamon, Mueller, Raeghan, YorkWilliams, Sophie L., Hagerty, Sarah, Bryan, Angela D., Hutchison, Kent E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870063/
https://www.ncbi.nlm.nih.gov/pubmed/29607409
http://dx.doi.org/10.1089/can.2017.0038
_version_ 1783309402680328192
author Bidwell, L. Cinnamon
Mueller, Raeghan
YorkWilliams, Sophie L.
Hagerty, Sarah
Bryan, Angela D.
Hutchison, Kent E.
author_facet Bidwell, L. Cinnamon
Mueller, Raeghan
YorkWilliams, Sophie L.
Hagerty, Sarah
Bryan, Angela D.
Hutchison, Kent E.
author_sort Bidwell, L. Cinnamon
collection PubMed
description Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines.
format Online
Article
Text
id pubmed-5870063
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-58700632018-03-30 A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains Bidwell, L. Cinnamon Mueller, Raeghan YorkWilliams, Sophie L. Hagerty, Sarah Bryan, Angela D. Hutchison, Kent E. Cannabis Cannabinoid Res Original Research Background: The development of novel cannabis research methods that are compatible with current federal regulations is imperative to conduct studies of the effects of legal market cannabis. There is very little research on higher strength, higher Δ9-tetrahydrocannabinol (THC), which has become increasingly available since legalization. Research on strains containing cannabidiol (CBD), a second primary, but nonpsychotomimetic, cannabinoid, is very limited. Materials and Methods: Using a novel observational methodology, regular cannabis users were asked to use one of two legal market cannabis strains that they purchased from a local dispensary (one strain containing 8% THC and 16% CBD (THC+CBD) and one containing a 17% THC concentration, but no CBD (THC). After using their suggested cannabis strain as they typically would for a 3-day period, participants returned to the laboratory immediately after their final use. Measures included a blood draw to measure cannabinoid blood levels and circulating cytokines, self-reported subjective drug effects, and verbal recall memory. Results: Analysis of CBD/THC concentration levels in the blood following the 3-day strain manipulation suggests that all, but one participant (n=23/24) followed instructions and used their assigned strain. Individuals in the THC group (n=11) smoked no more than their usual amount, and participants who used the THC+CBD (n=12) strain smoked more than their reported usual amount, but did not have significantly different THC+metabolite blood levels from the THC group. The THC+CBD strain was also associated with less desire to smoke, lower levels of subjective drug effects, and lower levels of circulating cytokines (TNF-α, IL-6, and IL-1β) immediately after use. Conclusions: Initial results support the feasibility of this novel observational methodology involving brief manipulation of strain use. Preliminary findings indicate that participants may self-titrate cannabis use based on cannabinoid concentration and the THC+CBD strain was associated with lower levels of cannabis craving, subjective intoxication, and circulating cytokines. Mary Ann Liebert, Inc. 2018-03-01 /pmc/articles/PMC5870063/ /pubmed/29607409 http://dx.doi.org/10.1089/can.2017.0038 Text en © L. Cinnamon Bidwell et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Bidwell, L. Cinnamon
Mueller, Raeghan
YorkWilliams, Sophie L.
Hagerty, Sarah
Bryan, Angela D.
Hutchison, Kent E.
A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title_full A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title_fullStr A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title_full_unstemmed A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title_short A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains
title_sort novel observational method for assessing acute responses to cannabis: preliminary validation using legal market strains
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870063/
https://www.ncbi.nlm.nih.gov/pubmed/29607409
http://dx.doi.org/10.1089/can.2017.0038
work_keys_str_mv AT bidwelllcinnamon anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT muellerraeghan anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT yorkwilliamssophiel anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT hagertysarah anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT bryanangelad anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT hutchisonkente anovelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT bidwelllcinnamon novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT muellerraeghan novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT yorkwilliamssophiel novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT hagertysarah novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT bryanangelad novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains
AT hutchisonkente novelobservationalmethodforassessingacuteresponsestocannabispreliminaryvalidationusinglegalmarketstrains